Repository logo
 

Real-world incidence of severe myelosuppression among chronic myeloid leukemia patients treated with imatinib in Ontario

dc.contributor.authorMcKenzie, Nathan
dc.contributor.copyright-releaseNot Applicableen_US
dc.contributor.degreeMaster of Scienceen_US
dc.contributor.departmentDepartment of Community Health & Epidemiologyen_US
dc.contributor.ethics-approvalReceiveden_US
dc.contributor.external-examinern/aen_US
dc.contributor.manuscriptsNot Applicableen_US
dc.contributor.thesis-readerDr. Sanja Stanojevicen_US
dc.contributor.thesis-readerDr. Martin Chasenen_US
dc.contributor.thesis-supervisorDr. Adrian Levyen_US
dc.date.accessioned2024-04-30T14:03:04Z
dc.date.available2024-04-30T14:03:04Z
dc.date.defence2024-04-18
dc.date.issued2024-04-29
dc.description.abstractImatinib, approved in 2001 for the treatment of chronic myeloid leukemia (CML) based on its remarkable efficacy, was associated with severe hematologic adverse events in clinical trials. This population-based retrospective cohort study compared the incidence of severe imatinib-induced myelosuppression in 1,683 Ontario CML patients, who initiated treatment between 2002 and 2020, to the incidence reported in imatinib’s phase III randomized controlled trial (RCT). The impact of demographic factors on myelosuppression risk was evaluated among the Ontario Drug Benefit (ODB) subjects. The ODB subjects differed in demographics and had lower incidences of neutropenia and thrombocytopenia, but a higher incidence of anemia compared to RCT patients. Risk of myelosuppression increased with age, mean daily dose, and severity of comorbidities, with no difference between sexes. These results emphasize the limitations of generalizing RCT results to broader populations and the importance of continued pharmacovigilance research to better understand drug safety beyond clinical trials.en_US
dc.identifier.urihttp://hdl.handle.net/10222/84163
dc.language.isoenen_US
dc.subjectChronic Myeloid Leukemiaen_US
dc.subjectImatiniben_US
dc.subjectMyelosuppressionen_US
dc.titleReal-world incidence of severe myelosuppression among chronic myeloid leukemia patients treated with imatinib in Ontarioen_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
NathanMcKenzie2024.pdf
Size:
2.33 MB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: